Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib for advanced NSCLC patients intolerant to osimertinib
ChiCTR2100046251Phase 4Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Safety. Started Apr 2021; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100046251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046251.